Story · Medicine & Biotech

Celltrion's Steqeyma wins EU panel backing for broader pediatric use

1 outlet · first reported by Korea Biomedical Review on

Celltrion said Monday that a European regulatory panel has recommended expanding the approved uses of its Stelara biosimilar Steqeyma (ustekinumab) to treat Crohn's disease and ulcerative colitis in children aged two and older.The European Medicines Agency's Committee for Medicinal Products for Huma (Korea Biomedical Review)

Coverage, in order

  1. Korea Biomedical Review South Korea obscure
    Celltrion's Steqeyma wins EU panel backing for broader pediatric use

    Celltrion said Monday that a European regulatory panel has recommended expanding the approved uses of its Stelara biosimilar Steqeyma (ustekinumab) to treat Crohn's disease and ulcerative colitis in children aged two and older.The European Medicines Agency's Committee for Medicinal Products for Huma

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.